ImmunityBio

ImmunityBio is a life sciences company that focuses on immunotherapy.[1]

History

In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.[1][2]

On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund monkey trials.[3] The company "hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020."[3]

References

"NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter". BioSpace.com. 14 April 2020.
Cross, Ryan (12 May 2020). "Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?". Chemical & Engineering News. 98 (19).
Cohen, Jon (1 June 2020). "Operation Warp Speed selects billionaire scientist's COVID-19 vaccine for monkey tests". American Association for the Advancement of Science. Science (magazine).

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[bsib-1] "NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter". BioSpace.com. 14 April 2020.

[rccen-2] Cross, Ryan (12 May 2020). "Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?". Chemical & Engineering News. 98 (19).

[opws-3] Cohen, Jon (1 June 2020). "Operation Warp Speed selects billionaire scientist's COVID-19 vaccine for monkey tests". American Association for the Advancement of Science. Science (magazine).